Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange.  The share capital increases relating to the issuance of the Consideration Shares and the Private Placement Shares […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!